Bluebird Bio Withdraws Zynteglo From Germany Over Pricing
Germany Is The Only Country Where the Gene Therapy Was Marketed
After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.
You may also be interested in...
Novartis has failed to reach a reimbursement agreement to keep its first-in-class advanced breast cancer drug on the German market, but it is pressing on with plans to expand market access for the product across Europe. It is also working on securing regulatory approval to use Piqray in a broader patient population that would carve out a more meaningful place in the relevant treatment pathway.
Lawyer and industry expert Alexander Natz sets out some important dos and don’ts for securing a successful launch of an advanced therapy in Germany.
Once the darling of biotech investors, Bluebird Bio’s go-it-alone strategy with Zynteglo has not paid off as German launch plans stall.